Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omnitrenidol
- Development stage
- Phase 4
- Lead developer
- IT3 Medical
- Modality
- Small Molecules
- Administration
- Intraarticular, Intramuscular, Percutaneous
01
Overview
**Omnitrenidol** is a prescription injection-system kit containing the small-molecule local anesthetic **lidocaine hydrochloride** and the synthetic corticosteroid **triamcinolone acetonide**. Lidocaine blocks voltage-gated sodium-channel-mediated neuronal impulse conduction to produce local or regional anesthesia, while triamcinolone acetonide activates glucocorticoid receptors to suppress inflammatory signaling. The kit is intended for procedural local anesthesia and corticosteroid injection use, including infiltration and nerve-block-related administration routes. The FDA label identifies IT3 Medical as the product packager and lists the product as an abbreviated new drug application product. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e31a76e5-719c-4b4d-8bda-5af71a3e377b))
- Brand names
- Omnitrenidol
- Other names
- lidocaine hydrochloride + triamcinolone acetonideOmnitrenidol Injection System
02
Targets
SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on Omnitrenidol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omnitrenidol.